Su1803 - Correlation of Endoscopic and Clinical Endpoints During Induction Therapy in Patients with Moderate to Severe Crohn's Disease: Analysis from Celest Study
William J. Sandborn(University of San Diego), Ana P. Lacerda(AbbVie (United States)), Fabio Cataldi(Pfizer (United States)), James D. Lewis(University of Pennsylvania), Walter Reinisch(Medical University of Vienna), Brian G. Feagan(Western University), David T. Rubin(University of California System), Wen Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Venkata Sasikiran Goteti, Silvio Danese(IRCCS Ospedale San Raffaele), Qian Zhou(Nanjing Foreign Language School)
Cited by 1
Related Papers
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
|Nature Medicine|2013|4.4k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k